HBsAg – Quantitative (CMIA)

Hepatitis B, a viral infection causing liver inflammation and potentially leading to severe liver damage, cirrhosis, or liver cancer, spreads through contact with infected blood or body fluids. Those at elevated risk include healthcare professionals, intravenous drug users, individuals engaging in unprotected sex, and newborns of infected mothers. Common symptoms include abdominal pain, dark urine, fever, joint pain, loss of appetite, nausea, vomiting, weakness, fatigue, and jaundice. The HBsAg – Quantitative (CMIA) test, a pivotal diagnostic tool, involves obtaining a small blood sample using a sterile needle from the patient’s arm vein. Using chemiluminescence microparticle immunoassay (CMIA) technology, the laboratory analyzes the blood sample for Hepatitis B surface antigen (HBsAg) levels. A positive diagnosis prompts various treatment options, including antiviral medications like tenofovir or entecavir, mitigating viral replication and reducing the risk of liver complications. Lifestyle adjustments such as avoiding alcohol and refraining from specific liver-harming medications are also recommended. For those considering testing with Hypro Diagnostics, the process is user-friendly. Patients can effortlessly choose the HBsAg – Quantitative (CMIA) panel on the website, selecting a convenient time slot. Results are delivered promptly within 69 hours, ensuring accurate diagnoses and facilitating timely treatment. Early detection through this highly accurate panel is crucial, allowing individuals to take proactive steps to safeguard their liver and manage Hepatitis B effectively, preventing potential complications.